

DESCRIPTION

| | |
|-------------------------------------|--|
| Source | Human embryonic kidney cell, HEK293-derived human CEACAM-20 protein Gln31-Gly450, with a C-terminal 6-His tag Accession # Q6UY09-1 |
| N-terminal Sequence Analysis | Gln31 inferred from enzymatic pyroglutamate treatment revealing Leu32 |
| Predicted Molecular Mass | 47 kDa |


SPECIFICATIONS

| | |
|------------------------|--|
| SDS-PAGE | 73-84 kDa, under reducing conditions |
| Activity | Measured by the ability of the immobilized protein to support the adhesion of the L Cells mouse fibroblast cell line. The ED ₅₀ for this effect is 0.25-1.5 µg/mL. |
| Endotoxin Level | <0.10 EU per 1 µg of the protein by the LAL method. |
| Purity | >95%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
| Formulation | Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details. |

PREPARATION AND STORAGE

| | |
|--------------------------------|---|
| Reconstitution | Reconstitute at 500 µg/mL in PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | <p>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</p> <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -20 to -70 °C under sterile conditions after reconstitution. |

DATA



BACKGROUND

Carcinoembryonic antigen-related cell adhesion molecule-20 (CEACAM-20) is a member of the CEACAM subfamily of glycoproteins in the immunoglobulin (Ig) superfamily. Mature human CEACAM-20 consists of a 420 amino acid (aa) extracellular domain (ECD), a 21 aa helical transmembrane segment, and a 114 aa cytoplasmic domain. The extracellular domain possesses four IgC2-like domains which are stabilized by disulfide bonds, as well as several predicted glycosylation sites (1-5). The extracellular domain of CEACAM-20 is also unique among the CEACAMs because it contains a truncated IgV-like N domain (2). Within the ECD, human CEACAM-20 shares 64% and 62% aa identity with the mouse and rat CEACAM-20, respectively. The cytoplasmic domain is unusually long compared to most other CEACAMs and is predicted to contain four tyrosine phosphorylation sites, two of which correspond to the immune-receptor tyrosine-based activation motif (ITAM) (2, 3). Human CEACAM proteins have been linked to numerous intercellular-adhesion and intracellular signaling processes including cell adhesion, growth, and recognition, differentiation, angiogenesis, and apoptosis (7, 8). Human CEACAM-20 expression is limited to the reproductive system and the intestinal tract, with the highest levels of expression found in the small intestine and prostate (2, 3). An *in vitro* model of human prostate morphogenesis showed that CEACAM-20 is co-expressed with CEACAM-1 and plays a critical role in the formation of prostate organoids, making it a marker for prostate cancer (2). Although the exact mechanism is not fully understood, CEACAM-20 may promote the proliferation of intestinal epithelial cells (IECs) (9). There is evidence suggesting CEACAM-20 can induce the production of chemokines like interleukin (IL)-8 and stimulate inflammatory responses in colitis and Crohn's disease (6). CEACAM-20 is also thought to act as a physiological substrate for SAP-1 in the intestinal epithelium (10).

References:

1. Tchoupa, A. *et al.* (2014) *J Cell Commun Signal* **12**:27.
2. Zhang, H. *et al.* (2013) *PLoS ONE* **8**:e53359.
3. Zebhauser, R. *et al.* (2005) *Genomics* **86**:566.
4. Beauchemin, N. Arabzadeh, A. (2013) *Cancer Metastasis Rev* **32**(3):643.
5. Kuespert, K. *et al.* (2006) *Curr Opin Cell Biol* **18**:565.
6. Murata, Y. *et al.* (2015) *PNAS* E4264.
7. Obrink, B. (1997) *Curr Opin Cell Biol* **9**:616.
8. Horst, AK. Wagener, C. (2004) *Handb Exp Pharmacol* 283.
9. Kitamura, Y. *et al.* (2015) *Genes to Cells* **20**:578.
10. Kotani, T. *et al.* (2016) *Expert Review of Gastroenterology & Hepatology*. **10**:1313.